EA202090688A1 - Бис-амидные соединения, активирующие саркомер, и варианты их применения - Google Patents

Бис-амидные соединения, активирующие саркомер, и варианты их применения

Info

Publication number
EA202090688A1
EA202090688A1 EA202090688A EA202090688A EA202090688A1 EA 202090688 A1 EA202090688 A1 EA 202090688A1 EA 202090688 A EA202090688 A EA 202090688A EA 202090688 A EA202090688 A EA 202090688A EA 202090688 A1 EA202090688 A1 EA 202090688A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sarcomer
variants
amide
activating
bis
Prior art date
Application number
EA202090688A
Other languages
English (en)
Inventor
Льюк Эшкрафт
Алессандро Боэсио
Джон Батлер
Аруп Чандра
Чихюань Чуанг
Скотт Е. Коллиби
Миккел Дебенедетто
Винсент Димасса
Расселл Грасеффа
Джастин Малиновски
Дэвид Мебиус
Брэдли П. Морган
Джошуа Пэйетт
Антонио Ромеро
Дэвид мл. Ст. Джин
Ричард Варгас
Джон Йоуман
Ханьмо Чжан
Алан Чэн
Феликс Гонсалес Лопес де Турисо
Майкл Гарретт Джонсон
Original Assignee
Эмджен Инк.
Сайтокинетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк., Сайтокинетикс, Инк. filed Critical Эмджен Инк.
Publication of EA202090688A1 publication Critical patent/EA202090688A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

В настоящем изобретении представлены соединение формулы (I) или его фармацевтически приемлемая соль, фармацевтические композиции, содержащие соединение по настоящему изобретению, способ получения соединений по настоящему изобретению и варианты их терапевтического применения.
EA202090688A 2017-09-13 2018-09-13 Бис-амидные соединения, активирующие саркомер, и варианты их применения EA202090688A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557846P 2017-09-13 2017-09-13
PCT/US2018/050793 WO2019055590A1 (en) 2017-09-13 2018-09-13 SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF

Publications (1)

Publication Number Publication Date
EA202090688A1 true EA202090688A1 (ru) 2020-07-06

Family

ID=63794635

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090688A EA202090688A1 (ru) 2017-09-13 2018-09-13 Бис-амидные соединения, активирующие саркомер, и варианты их применения

Country Status (22)

Country Link
US (5) US10723720B2 (ru)
EP (1) EP3681882A1 (ru)
JP (1) JP7308816B2 (ru)
KR (1) KR20200054237A (ru)
CN (1) CN111601798B (ru)
AR (1) AR112804A1 (ru)
AU (1) AU2018332887B2 (ru)
BR (1) BR112020004800A2 (ru)
CA (1) CA3075669A1 (ru)
CL (1) CL2020000610A1 (ru)
CO (1) CO2020002745A2 (ru)
CR (1) CR20200116A (ru)
EA (1) EA202090688A1 (ru)
IL (1) IL272573B2 (ru)
JO (1) JOP20200059A1 (ru)
MA (1) MA50173A (ru)
MX (2) MX2020002696A (ru)
PH (1) PH12020500446A1 (ru)
SG (1) SG11202001377PA (ru)
TW (1) TWI790281B (ru)
UY (1) UY37879A (ru)
WO (1) WO2019055590A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50173A (fr) 2017-09-13 2020-07-29 Amgen Inc Composés activateurs de bisamide sarcomère et leurs utilisations
KR20210016545A (ko) * 2018-05-29 2021-02-16 오메로스 코포레이션 Masp-2 억제제 및 사용 방법
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
US20220185791A1 (en) * 2019-03-12 2022-06-16 Amgen Inc. Polymorphs of a cardiac troponin activator
AU2020234995A1 (en) * 2019-03-12 2021-10-21 Amgen Inc. Polymorphs and cocrystals of a cardiac troponin activator
AU2020317609A1 (en) * 2019-07-23 2022-02-24 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
JP2023504542A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
EP4168393A1 (en) * 2020-06-17 2023-04-26 Merck Sharp & Dohme LLC 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
WO2022198196A1 (en) 2021-03-15 2022-09-22 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof
WO2023122325A2 (en) * 2021-12-23 2023-06-29 Regents Of The University Of Michigan Meta anilide compounds and methods for use of the same to treat diseases and disorders

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662529B2 (ja) * 1984-07-13 1994-08-17 三共株式会社 アミノ酸誘導体
US5952307A (en) 1994-01-21 1999-09-14 Georgia Tech Research Corp. Basic α-aminoalkylphosphonate derivatives
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
GB9708119D0 (en) 1997-04-22 1997-06-11 Glaxo Group Ltd Chemical compounds
AU1082901A (en) 1999-10-18 2001-04-30 National Jewish Medical And Research Center Method for modulation of cell phenotype
US20020002171A1 (en) 2000-01-28 2002-01-03 Chalquest Richard R. Materials and methods for killing nematodes and nematode eggs
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
AU2002237733A1 (en) 2000-11-07 2002-06-18 Board Of Regents, The University Of Texas System Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
JP4361800B2 (ja) 2001-12-21 2009-11-11 サイトキネティックス， インコーポレイテッド 心不全を処置するための組成物および方法
US20030158186A1 (en) 2001-12-21 2003-08-21 Fady Malik Compositions and methods for treating heart failure
WO2004064730A2 (en) 2003-01-14 2004-08-05 Cytokinetics, Inc. Compounds, compositions and methods
ATE524452T1 (de) * 2003-03-27 2011-09-15 Cytokinetics Inc Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen.
US20050043260A1 (en) 2003-04-21 2005-02-24 Baylor College Of Medicine Wnt as a factor for cardiac myogenesis
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
JP2005298628A (ja) 2004-04-09 2005-10-27 Sumitomo Chemical Co Ltd オレフィン重合触媒成分及びオレフィン重合体の製造方法
RU2410384C2 (ru) 2004-06-17 2011-01-27 Цитокинетикс, Инк. Соединения, композиции и способы их использования
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
EP1959960B1 (en) 2005-12-15 2013-04-10 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
WO2007078839A2 (en) 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
WO2007089805A2 (en) 2006-01-31 2007-08-09 The General Hospital Corporation Anti-hypertrophic effects and inotropic effects of picot
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
EP2768517A4 (en) 2011-10-17 2015-03-11 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
CN117736134A (zh) * 2012-01-12 2024-03-22 耶鲁大学 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
MX2015012416A (es) 2013-03-14 2016-04-07 Amgen Inc Compuestos heterociclicos y sus usos.
WO2015103527A1 (en) 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
WO2015142001A2 (ko) 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
MX2022007040A (es) 2015-01-22 2022-06-24 Myokardia Inc Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd).
BR112017019751A2 (pt) 2015-03-18 2018-05-29 Arvinas Inc composto bifuncional, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou um distúrbio, e para degradar uma proteína alvo em uma célula
WO2016201288A1 (en) 2015-06-12 2016-12-15 Brown University Novel antibacterial compounds and methods of making and using same
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法
AR105809A1 (es) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc Compuestos para el tratamiento de trastornos médicos
KR20160108281A (ko) 2016-09-06 2016-09-19 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
US11040956B2 (en) 2017-06-30 2021-06-22 Amgen Inc. Synthesis of omecamtiv mecarbil
MA50173A (fr) 2017-09-13 2020-07-29 Amgen Inc Composés activateurs de bisamide sarcomère et leurs utilisations
PT3594199T (pt) 2018-07-09 2020-09-04 Amgen Inc 2-fluoro-3-nitrotolueno cristalino e processo para a sua preparação
US11465969B2 (en) 2018-08-17 2022-10-11 Cytokinetics, Inc. Salts and crystal forms of omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
AU2020234995A1 (en) 2019-03-12 2021-10-21 Amgen Inc. Polymorphs and cocrystals of a cardiac troponin activator
US20220185791A1 (en) 2019-03-12 2022-06-16 Amgen Inc. Polymorphs of a cardiac troponin activator

Also Published As

Publication number Publication date
CA3075669A1 (en) 2019-03-21
US20200223829A1 (en) 2020-07-16
JP7308816B2 (ja) 2023-07-14
AU2018332887A1 (en) 2020-02-27
AR112804A1 (es) 2019-12-11
WO2019055590A1 (en) 2019-03-21
UY37879A (es) 2019-03-29
TWI790281B (zh) 2023-01-21
US10899746B2 (en) 2021-01-26
JOP20200059A1 (ar) 2020-03-12
US11299479B1 (en) 2022-04-12
SG11202001377PA (en) 2020-03-30
US20220281850A1 (en) 2022-09-08
KR20200054237A (ko) 2020-05-19
TW201920096A (zh) 2019-06-01
US20200223830A1 (en) 2020-07-16
MX2022014864A (es) 2022-12-15
EP3681882A1 (en) 2020-07-22
CN111601798A (zh) 2020-08-28
MX2020002696A (es) 2020-09-25
BR112020004800A2 (pt) 2020-09-24
US11254658B2 (en) 2022-02-22
CN111601798B (zh) 2023-08-11
IL272573B2 (en) 2023-10-01
IL272573B1 (en) 2023-06-01
US20190077793A1 (en) 2019-03-14
JP2020533347A (ja) 2020-11-19
CO2020002745A2 (es) 2020-06-19
US10723720B2 (en) 2020-07-28
PH12020500446A1 (en) 2020-11-09
MA50173A (fr) 2020-07-29
CR20200116A (es) 2021-04-28
IL272573A (en) 2020-03-31
CL2020000610A1 (es) 2020-11-13
AU2018332887B2 (en) 2022-12-08
US11780826B2 (en) 2023-10-10

Similar Documents

Publication Publication Date Title
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
PH12018500591A1 (en) Heterocyclic compounds and uses thereof
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
EA201692542A1 (ru) Индановые и индолиновые производные и их применение в качестве активаторов растворимой гуанилатциклазы
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA202090368A1 (ru) Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1)
EA201692298A1 (ru) Производные карбоксамидов
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA202190064A1 (ru) Цианотриазоловые соединения и варианты их применения
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
EA202091293A1 (ru) Производные пиридинона и их применение в качестве селективных ингибиторов alk-2
EA202192760A1 (ru) Трициклические соединения
EA202190458A1 (ru) Составы, содержащие дендример
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
EA202190689A1 (ru) Производные хинолина в качестве ингибиторов интегрина альфа4бета7
EA202190707A1 (ru) Ингибиторы о-гликопротеин-2-ацетамидо-2-деокси-3-d-глюкопиранозидазы